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Abstract
Background: Prior antibiotic exposure has been associated with the emergence of antibiotic resistance in
subsequent bacterial infections, whose outcomes are typically worse than similar infections with more antibiotic
susceptible infections. The influence of prior antibiotic exposure on hospital length of stay (LOS) and costs in
patients with severe sepsis or septic shock attributed to Gram-negative bacteremia has not been previously
examined.
Methods: A retrospective cohort study of hospitalized patients (January 2002-December 2007) was performed at
Barnes-Jewish Hospital, a 1200-bed urban teaching hospital. Patients with Gram-negative bacteremia complicated
by severe sepsis or septic shock had data abstraction from computerized medical records. We examined a
consecutive cohort of 754 subjects (mean age 59.3 ± 16.3 yrs, mean APACHE II 23.7 ± 6.7).
Results: Escherichia coli (30.8%), Klebsiella pneumoniae (23.2%), and Pseudomonas aeruginosa (17.6%) were the most
common organisms isolated from blood cultures. 310 patients (41.1%) had exposure to antimicrobial agents in the
previous 90 days. Patients with recent antibiotic exposure had greater inappropriate initial antimicrobial therapy
(45.4% v. 21.2%; p < 0.001) and hospital mortality (51.3% v. 34.0%; p < 0.001) compared to patients without recent
antibiotic exposure. The unadjusted median LOS (25th percentile, 75th percentile) following sepsis onset in patients
with prior antimicrobial exposure was 13.0 days (5.0 days, 24.0 days) compared to 8.0 days (5.0 days, 14.0 days) in
those without prior antimicrobial exposure (p < 0.001). In a Cox model controlling for multiple confounders, prior
antibiotic exposure independently correlated with remaining hospitalized (Adjusted hazard ratio: 1.473, 95% CI:
1.297-1.672, p < 0.001). Adjusting for potential confounders indicated that prior antibiotic exposure independently
increased median attributable LOS by 5.0 days. Similarly, total hospital costs following sepsis onset was significantly
greater among patients with prior antimicrobial exposure (median values: $94,737 v. $21,329; p < 0.001).
Conclusions: Recent antibiotic exposure is associated with increased LOS and hospital costs in Gram-negative
bacteremia complicated by severe sepsis or septic shock. Clinicians and hospital administrators should consider the
potential impact of recent antibiotic exposure when formulating empiric treatment decisions for patients with
serious infections attributed to Gram-negative bacteria.
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Background
Knowledge of the clinical and economic impact of anti-
microbial resistance is useful to influence programs and
behavior in healthcare facilities, to guide policy makers
and funding agencies, to define the prognosis of indivi-
dual patients and to stimulate interest in developing
new antimicrobial agents and therapies [1]. One of the
most misunderstood issues is how to measure cost
appropriately when analyzing the antibiotic treatment of
infections. Although imperfect, existing data show that
there is an association between antimicrobial resistance
in Staphylococcus aureus, enterococci and Gram-nega-
tive bacilli and increases in mortality, morbidity, length
of hospitalization and cost of healthcare [1]. Patients
with infections due to antimicrobial-resistant organisms
have greater hospital costs (US$6000-30,000) than do
patients with infections due to antimicrobial-susceptible
organisms [1,2]. Given limited budgets, imperfect knowl-
edge of the clinical and economic impact of antibiotic-
resistant bacterial infections, coupled with the benefits
of specific interventions targeted to reduce these infec-
tions or to improve their treatment, more optimal man-
agement strategies to control and improve antibiotic
utilization are needed. The traditional way of accounting
for antimicrobial costs in terms of pharmacy acquisition
expenditures for antibiotics may not be appropriate
when discussing the treatment of antibiotic resistant
infections. Instead, increasing evidence suggests that the
most cost-effective approach for the treatment of such
infections is to provide appropriate therapy in a timely
manner [3-6].
Inappropriate initial antimicrobial therapy, defined as
an antimicrobial regimen that lacks in vitro activity
against the isolated organism(s) responsible for the infec-
tion, has been associated with excess mortality and
lengths of stay in patients with severe sepsis and septic
shock [5,7-11]. This is largely related to increasing bac-
terial resistance to antibiotics as a result of their greater
use and limited availability of new agents [12,13]. Escalat-
ing rates of antimicrobial resistance lead many clinicians
to empirically treat critically ill patients with presumed
infection with a combination of broad-spectrum antibio-
tics, which can perpetuate the cycle of increasing resis-
tance [14]. Conversely, inappropriate initial antimicrobial
therapy can lead to treatment failures and adverse patient
outcomes [15]. Therefore, clinicians need to be aware of
when it is clinically and economically reasonable to use
newer, broad-spectrum antibiotics. Prior antibiotic expo-
sure may represent an important marker for decision
making, especially as new broad-spectrum antibiotics
begin to enter the clinical setting.
The most recent Surviving Sepsis Guidelines recom-
mend empiric combination therapy targeting Gram-
negative bacteria, particularly for patients with known
or suspected Pseudomonas infections, as a means to
decrease the likelihood of administering inappropriate
initial antimicrobial therapy [16]. The choice of an anti-
microbial regimen that is active against the causative
pathogen(s) is increasingly problematic as the treating
physician usually does not know the susceptibilities of
the pathogen(s) for the selected empiric antibiotics at
the time of antibiotic prescription. We previously
showed that recent antibiotic exposure is associated
with increased hospital mortality in Gram-negative bac-
teremia complicated by severe sepsis or septic shock,
primarily due to inappropriate initial treatment [17].
Therefore, we performed an investigation to determine
whether recent antibiotic exposure also resulted in
increased LOS and hospital costs among patients with
severe sepsis or septic shock attributed to Gram-nega-
tive bacteremia.
Methods
Study Location and Patient Population
This study was conducted at a university-affiliated,
urban teaching hospital: Barnes-Jewish Hospital (1200
beds). Over a six-year period (January 2002-December
2007) all hospitalized patients with Gram-negative bac-
teremia were eligible for inclusion. This study was
approved by the Washington University School of Medi-
cine Human Studies Committee. Barnes-Jewish Hospital
is part of BJC HealthCare, one of the largest nonprofit
health care organizations in the United States, delivering
services to residents primarily in the greater St. Louis,
southern Illinois and mid-Missouri regions. BJC serves
urban, suburban and rural communities and includes 13
hospitals and multiple community health locations
which share a common informatics system for medical
records.
Study Design and Data Collection
Utilizing a retrospective cohort study design, patients
with Gram-negative sepsis were identified by the pre-
sence of a blood culture positive only for Gram-negative
bacteria combined with primary or secondary ICD-9-
CM codes indicative of acute organ dysfunction. Patient
specific baseline characteristics and process of care vari-
ables were collected from the automated hospital medi-
cal record, microbiology database, and pharmacy
database of Barnes-Jewish Hospital. Data collection for
all patients was uniform regardless of the initial location
of their hospitalization (intensive care unit or general
hospital ward). Only the first episode of severe sepsis or
septic shock attributed to Gram-negative bacteremia
was evaluated. Electronic inpatient and outpatient medi-
cal records available for all patients in the BJC
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Healthcare system were reviewed to determine prior
antibiotic exposure.
The baseline characteristics collected included: age,
gender, race, past history of congestive heart failure,
chronic obstructive pulmonary disease, diabetes mellitus,
chronic liver disease, underlying malignancy, and end-
stage renal disease requiring dialysis. The Acute Physiol-
ogy and Chronic Health Evaluation (APACHE) II [18]
and Charlson co-morbidity scores were calculated based
on clinical data present during the twenty-four hours
after the positive blood cultures were obtained. This was
done to accommodate patients with community-
acquired and healthcare-associated community-onset
infections who only had clinical data available after
blood cultures were drawn. The primary outcome vari-
able was total hospital LOS. Secondary outcomes evalu-
ated included: total hospital costs and proportion of
patients receiving inappropriate initial antimicrobial
therapy.
Definitions
All definitions were prospectively selected prior to initia-
tion of the study. LOS after onset of severe sepsis or
septic shock was defined as the number of hospital days
following the drawing of the first positive blood culture
in eligible patients. To be included in the analysis
patients had to meet criteria for severe sepsis based on
discharge ICD-9-CM codes for acute organ dysfunction
as previously described [19]. The organs of interest
included the heart, lungs, kidneys, bone marrow (hema-
tologic), brain, and liver. Patients were classified as hav-
ing septic shock if vasopressors (norepinephrine,
dopamine, epinephrine, phenylephrine or vasopressin)
were initiated within 24 hours of the blood culture col-
lection date and time.
Antimicrobial treatment was classified as appropriate
if the initially prescribed antibiotic regimen was active
against the identified pathogen based on in vitro sus-
ceptibility testing and administered within 24 hours fol-
lowing blood culture collection. For patients with
polymicrobial infection the initial antimicrobial regimen
had to be active against all identified pathogens in order
to be classified as appropriate. Appropriate antimicrobial
treatment also had to be prescribed for at least 24
hours. However, the total duration of antimicrobial ther-
apy was at the discretion of the treating physicians.
Prior antibiotic exposure was any exposure to an anti-
biotic within the preceding 90 days.
Total hospital costs following sepsis onset were
derived from a summation of costs incurred across hos-
pital cost centers, including room and board, pharmacy,
radiology, and laboratory. Cost data were directly
reported from the Barnes-Jewish Hospital accounting
department; cost:charge ratios were not used. All
reported costs represent actual costs for the administra-
tion of patient care as determined by the individual
departmental finance sections.
Antimicrobial Monitoring
From January 2002 through the present, Barnes-Jewish
Hospital utilized an antibiotic control program to help
guide antimicrobial therapy. During this time the use of
cefepime and gentamicin were unrestricted. However,
initiation of intravenous ciprofloxacin, imipenem, mero-
penem, or piperacillin/tazobactam was restricted and
required pre-authorization from either a clinical phar-
macist or infectious diseases physician. Each intensive
care unit had a clinical pharmacist who reviewed all
antibiotic orders to insure that dosing and interval of
antibiotic administration was adequate for individual
patients based on body size, renal function, and the
resuscitation status of the patient. After daytime hours
the on call clinical pharmacist reviewed and approved
the antibiotic orders. The initial antibiotic dosages
employed for the treatment of Gram-negative infections
at Barnes-Jewish Hospital were as follows: cefepime, 1
to 2 grams every eight hours; pipercillin-tazobactam, 4.5
grams every six hours; imipenem 0.5 grams every six
hours; meropenem, 1 gram every eight hours; ciproflox-
acin, 400 mg every eight hours; gentamicin, 5 mg/kg
once daily.
Antimicrobial Susceptibility Testing
The microbiology laboratory performed antimicrobial
susceptibility of the Gram-negative blood isolates using
the disk diffusion method according to guidelines and
breakpoints established by the Clinical Laboratory and
Standards Institute (CLSI) and published during the
inclusive years of the study [20,21].
Data Analysis
Categorical variables were compared with the Fisher’s
exact test. We compared normally distributed continu-
ous variables via the Student’s t-test while employing
the Mann-Whitney U test for non-parametric, continu-
ous factors. We constructed curves for LOS after onset
of severe sepsis or septic shock according to the meth-
ods of Kaplan and Meier to examine time to hospital
discharge as a function of prior antibiotic exposure.
These curves were compared via log-rank test. All tests
were two tailed and unpaired while, a p value of < 0.05
was assumed to represent statistical significance.
To evaluate the independent impact of prior antibiotic
exposure on hospital LOS, we created a Cox-propor-
tional hazards model. Prior to completing the model we
determined that the proportional hazards assumption
was not violated. A priori, we placed in this model fac-
tors we felt that were biologically likely to affect hospital
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LOS. Specifically, we controlled for age, gender, co-mor-
bidities, infection source, severity of illness, pre-infection
hospital LOS (for nosocomial infections), inappropriate
antibiotic therapy, prior hospitalization, and hospital-
onset infection. Variables were examined to assess for
co-linearity. We then re-calculated the Kaplan-Meier
survival curves for the probability of remaining hospita-
lized controlling for each independent factor which
remained significant in the Cox model but plotted two
separate curves - one for patients without prior antibio-
tic exposure and another for those with prior antibiotic
exposure. From this we determined the median adjusted
difference in hospital LOS between the two groups. The
correlation between LOS and hospital costs was assessed
using Spearman’s rank correlation coefficient. All ana-
lyses were completed using SPSS 11.0 (SPSS, Chicago,
IL).
Results
Seven hundred fifty-four consecutive patients with bac-
teremic Gram-negative severe sepsis or septic shock
were included in the study. The mean age was 59.3 ±
16.3 years (range, 18-99 years) with 394 (52.3%) males
and 360 (47.7%) females (Table 1). There were 421
(55.8%) medical patients and 333 (44.2%) surgical
patients. The mean duration of hospitalization was 10.2
± 14.4 days (range, 1-96) at the time severe sepsis or
septic shock occurred. The mean APACHE II score was
23.7 ± 6.7 (range, 4-43) with the majority of patients
requiring vasopressors (58.5%) and mechanical ventila-
tion (55.3%). Escherichia coli (30.8%), Klebsiella pneumo-
niae (23.2%), Pseudomonas aeruginosa (17.6%),
Enterobacter species (10.1%), Acinetobacter species
(8.4%), Proteus mirabilis (4.9%), Serratia marcescens
(4.0%), and Stenotrophomonas maltophilia (1.9%) were
the most common organisms isolated from blood cul-
tures. Fifty-six (7.4%) patients had polymicrobial
bacteremia.
Three hundred-ten (41.1%) patients had prior antibio-
tic exposure during the preceding 90 days. Of these,
cefepime was the most common agent with previous
exposure (50.0%) followed by ciprofloxacin (32.6%), imi-
penem or meropenem (28.7%), pipercillin-tazobactam
(19.0%), and aminoglycosides (14.5%). Most prior anti-
biotic exposure was during the same hospitalization and
within 21 days of severe sepsis onset for patients with
healthcare-associated hospital-onset infections (77.9%).
Among patients with healthcare-associated community-
onset infections prior antibiotic exposure was either out-
patient administered (56.7%) or administered during a
hospitalization occurring within 90 days of infection
onset (43.3%). When compared to cases with no prior
antibiotic exposure, patients with prior exposure were
significantly more likely to have healthcare-associated
hospital-onset sepsis, sepsis occur in the intensive care
unit setting, and a longer duration of stay prior to sepsis
onset (Table 1). Patients with prior antibiotic exposure
were also significantly younger, had lower Charlson co-
morbidity scores, were more likely to have a pulmonary
source of infection, and to require mechanical ventila-
tion and vasopressor support.
Patients with prior antibiotic exposure had higher
rates of inappropriate initial antimicrobial therapy
(45.5% v. 21.2% p < 0.001) and hospital mortality (51.3%
v. 34.0%, p < 0.001) compared to patients without prior
antibiotic exposure. Inappropriate antibiotic therapy of
severe sepsis was more likely to be associated with prior
exposure to cefepime (37.4% v.12.9%; p < 0.001), cipro-
floxacin (25.1% v. 8.1%; p < 0.001), ceftriaxone (7.2% v.
1.3%; p < 0.001), and imipenem (13.6% v. 5.4%; p <
0.001) compared to appropriate therapy. Similarly, prior
exposure to cefepime, ciprofloxacin, and imipenem were
associated with statistically longer hospital LOS.
Figure 1 reveals the probability of remaining hospita-
lized after the diagnosis of severe sepsis or septic shock
as a function of prior antibiotic exposure. Subjects receiv-
ing prior antibiotic exposure had an unadjusted median
increase of 5.0 days in LOS (13.0 days v. 8.0 days, p <
0.001). In a Cox model adjusting for multiple co-variates
(see Table 2), prior antibiotic exposure remained linked
with an increased probability of remaining hospitalized
after the onset of Gram-negative sepsis. The adjusted
hazard ratio related to prior antibiotic exposure equaled
1.473 (95% CI: 1.297-1.672). Other variables significantly
correlated with remaining hospitalized included pre-
infection length of stay, severity of illness, inappropriate
antibiotic therapy, hospital-onset infection, and a pul-
monary source of infection. After controlling for the
other factors displayed in Table 2, we estimate that prior
antibiotic exposure independently increased hospital
length of stay by approximately 5.0 days.
Figure 2 depicts the hospital costs following the onset
of Gram-negative sepsis for the main cost centers exam-
ined. Total median hospital costs were significantly
greater for patients with prior antibiotic exposure com-
pared to patients without prior antibiotic exposure
(median values: $94,737 [25th and 75th percentiles:
$53,941; $136,878] v. $21,329 [25th and 75th percentiles:
$11,403; $41,461]; p < 0.001). LOS and total hospital
costs following the onset of Gram-negative sepsis were
strongly correlated (Spearman’s rank correlation coeffi-
cient = 0.947; p < 0.001).
When only hospital survivors were examined, subjects
receiving prior antibiotic exposure had an unadjusted
median increase of 7.0 days in LOS (16.0 days v. 9.0
days, p < 0.001). Similarly, when only hospital survivors
were examined total median hospital costs were signifi-
cantly greater for patients with prior antibiotic exposure
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compared to patients without prior antibiotic exposure
(median values: $93,764 [25th and 75th percentiles:
$52,892; $134,310] v. $21,369 [25th and 75th percentiles:
$11,981; $39,760]; p < 0.001).
Discussion
Our study suggests that prior antibiotic exposure was
associated with greater LOS following the onset of Gram-
negative bacteremia complicated by severe sepsis or septic
shock. This observation was confirmed in an adjusted ana-
lysis of LOS and in a multivariate analysis controlling for
potential confounding variables. Not surprisingly, other
important determinants of prolonged LOS in the multi-
variate analysis included pre-infection onset hospital LOS,
inappropriate antibiotic therapy, severity of illness, and the
lungs as the source of infection.
Table 1 Baseline Characteristics*
Variable Prior Antibiotic Exposure (n = 310) No Prior Antibiotic Exposure (n = 444) P- value
Age (years) 56.9 ± 16.6 60.9 ± 16.0 0.001
Male 170 (54.8) 224 (50.5) 0.235
Infection Onset Type
Community-acquired 0 (0.0) 71 (16.0) <0.001
Healthcare-associated community-onset 30 (9.7) 236 (53.2)
Healthcare-associated hospital-onset 280 (90.3) 137 (30.9)
Duration of hospitalization prior to sepsis (days) 20.4 ± 17.1 3.2 ± 5.3 <0.001
Underlying Comorbidities
Congestive Heart Failure 53 (17.1) 91 (20.5) 0.243
Chronic Obstructive Lung Disease 62 (20.0) 74 (16.7) 0.241
Chronic Kidney Disease 39 (12.6) 70 (15.8) 0.221
Liver Disease 37 (11.9) 57 (12.8) 0.712
Active Malignancy 95 (30.6) 146 (32.9) 0.517
Diabetes 65 (21.0) 104 (23.4) 0.426
APACHE II score 23.5 ± 6.5 23.8 ± 6.9 0.525
Charlson co-morbidity score 4.3 ± 3.7 5.2 ± 3.6 0.002
In ICU when sepsis occurred 265 (85.5) 331 (74.5) <0.001
Vasopressors 207 (66.8) 234 (52.7) <0.001
Mechanical Ventilation 221 (71.3) 196 (44.1) <0.001
Drotrecogin alfa (activated) 8 (2.6) 23 (5.2) 0.077
Organ Dysfunction
Cardiovascular 214 (69.0) 253 (57.0) 0.001
Respiratory 238 (76.8) 228 (51.4) <0.001
Renal 163 (52.6) 240 (54.1) 0.690
Hepatic 24 (7.7) 31 (7.0) 0.693
Hematologic 88 (28.3) 141 (31.8) 0.322
Neurologic 17 (5.5) 31 (7.0) 0.407
Number of organ failures 2.4 ± 1.0 2.1 ± 1.1 <0.001
Source of Bacteremia#
Lungs 166 (53.5) 134 (30.2) <0.001
Urinary Tract 67 (21.6) 163 (36.7) <0.001
Central Venous Catheter 16 (5.2) 40 (9.0) 0.047
Intra-abdominal 64 (20.6) 73 (16.4) 0.141
Unknown 8 (2.6) 41 (9.2) <0.001
Values are expressed as number (%) and mean ± standard deviation.
APACHE = acute physiology and chronic health evaluation; ICU = intensive care unit.
*Data from hospital admission (demographics and underlying comorbidities) or within 24 hours of obtaining a positive blood culture in patients with severe
sepsis or septic shock.
#Defined using Centers for Disease Control criteria (www.cdc.gov/ncidod/dhqp/pdf/nnis/NosInfDefinitions.pdf)
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A likely explanation for the association we observed
between hospital LOS and prior antibiotic exposure is
the greater occurrence of antimicrobial resistance
among the causative pathogen(s) associated with sepsis
among patients having received prior antibiotic therapy.
We previously demonstrated that prior antibiotic expo-
sure was associated with a greater incidence of infection
attributed to Gram-negative bacteria that were either
antibiotic-resistant or multi-drug resistant [17]. Prior
antibiotic exposure was also associated with greater
administration of inappropriate initial antimicrobial
therapy which has been linked with excess mortality and
longer lengths of stay in septic patients [3-7]. Shorr et
al. evaluated the impact of a sepsis management
protocol that emphasized identification of septic
patients, aggressive fluid resuscitation, timely antibiotic
administration, and appropriateness of antibiotics [6].
Use of the sepsis protocol was associated with lower
hospital mortality and substantial institutional cost sav-
ings. The sepsis protocol significantly increased the use
of appropriate initial antibiotic therapy, despite the
initial use of potentially more costly antibiotic regimens,
and represents a strategy for enhancing resource utiliza-
tion while containing overall costs in hospitalized
patients with sepsis [6].
The findings from our study are consistent with those
observed by other investigators. Webster et al. recently
described resistance trends in Escherichia coli and Kleb-
siella pneumoniae bloodstream infections in Oxford-
shire, UK, over an 11 year period [22]. In their
univariate analysis multidrug resistance (OR 2.77, 95%
CI 1.23-6.22, p = 0.014), previous hospital admission
(OR 1.27, 95% CI 1.01-1.60, p = 0.041) and isolation of
Klebsiella pneumoniae (OR 1.53, 95% CI 1.05-2.22, p =
0.026) predicted a longer hospital LOS, as did age 7
years (OR 1.58, 95% CI 1.26-1.99, p < 0.0005). On mul-
tivariate analysis, multidrug resistance remained a strong
independent predictor of increased LOS. Similarly, Lau-
tenbach et al. examined the longitudinal trends in preva-
lence of imipenem-resistant Pseudomonas aeruginosa
(IRPA) from 2 centers from 1989 through 2006 [23].
Isolation of IRPA was associated with longer hospital
LOS after culture (p < .001) and greater hospital costs
after culture (p < .001) than was isolation of an imipe-
nem-susceptible strain. In multivariable analysis, IRPA
infection or colonization remained an independent risk
factor for both longer hospital LOS after culture and
greater hospital costs after culture. Although these
investigators did not specifically examine prior antibiotic
exposure as a risk factor, antibiotic-resistant bacterial
infection represents a good marker for having had such
exposure occur [12,13].
Our study is unique in identifying prior antibiotic
exposure as an independent risk factor for prolonged
LOS among patients with Gram-negative bacteremia
complicated by severe sepsis or septic shock. This obser-
vation suggests that clinicians should search for and
identify the presence of prior antibiotic exposure as an
important consideration when prescribing empiric anti-
biotic therapy to patients with severe sepsis or septic
shock. The identification of prior antibiotic exposure
should result in specific therapeutic interventions. For
example, clinicians should avoid antibiotics or antibiotic
classes to which the patient was previously exposed.
Additionally, severity of illness appears to play an
important role in determining which patients are at
greatest risk for adverse outcomes from inappropriate
antibiotic therapy [17]. Patients with shock or
Figure 1 Kaplan Meier curves showing the proportion of
patients remaining hospitalized after the onset of severe
sepsis or septic shock attributed to Gram-negative bacteremia.
The solid line represents patients without prior antibiotic exposure
and the broken line represents patients with prior antibiotic
exposure. P < 0.001 by Log-Rank test.





Prior antibiotic exposure 1.473 (1.297-1.672) 0.002
Pulmonary source of infection 1.670 (1.496-1.865) <0.001
APACHE II Score (1-point increments) 1.066 (1.057-1.076) <0.001
Inappropriate antibiotic therapy 1.390 (1.239-1.559) 0.004
Hospital-onset infection 1.486 (1.234-1.790) 0.034
Pre-culture length of stay (1-day
increments)
1.012 (0.008-1.016) 0.001
CI = confidence interval; APACHE = Acute Physiology and Chronic Health
Evaluation
Other variables included in the analysis for which the Cox-proportional
hazards model was adjusted included male gender, age (1-year increments),
underlying liver disease, underlying renal disease, underlying malignancy,
prior hospitalization (within 90 days), and Charlson co-morbidity score. Hazard
ratios greater than 1 indicate the factor is associated with a greater
probability of remaining hospitalized. Patients who died were censored at the
time of death because they did not reach the endpoint of “discharged alive
from hospital.”
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neutropenia, especially those with prior antibiotic expo-
sure, may benefit the most from initial combination
therapy that includes an aminoglycoside in order to
minimize the occurrence of inappropriate initial antimi-
crobial therapy [24,25].
There are several important limitations of our study that
should be noted. First, the study was performed at a single
center and the results may not be generalizable to other
institutions. However, the findings from other investiga-
tors corroborate the potential role of prior antibiotic expo-
sure as an important determinant of outcome, including
LOS, for patients with serious Gram-negative infections
[5-7,24]. Second, the retrospective and observational nat-
ure of this study limits our ability to establish causality
between prior antibiotic exposure and hospital LOS. The
retrospective design also restricts our ability to identify all
prior antibiotic exposure, especially outpatient exposure to
antimicrobial agents. However, we are confident that the
majority of all antibiotic exposure in the 90 days prior to
severe sepsis onset was captured by our data base, espe-
cially as it captures cli9nical data from both inpatient and
outpatient facilities. Third, our study may not have identi-
fied all of the factors contributing to length of stay in this
patient population. Fourth, we did not evaluate the num-
ber of days preceding hospital admission when prior anti-
biotic exposure occurred nor did we assess the total
number of days of prior antibiotic exposure. These could
be other important variables that influence patient out-
comes. Lastly, the presence of prior antimicrobial exposure
may not be easily identified, especially in patients without
easily accessible medical records describing recent outpati-
ent and inpatient treatments. This is an important limita-
tion for using the risk factor of prior antibiotic exposure in
daily patient management decision making.
Conclusions
In conclusion, we observed that prior antibiotic expo-
sure is relatively common and associated with adverse
outcomes including greater hospital LOS among
patients with Gram-negative bacteremia complicated by
severe sepsis or septic shock. This observation suggests
that clinicians treating patients with suspected Gram-
negative bacteremia or sepsis should attempt to identify
whether prior antibiotic exposure occurred. In clinical
situations where recent antibiotic exposure is likely, but
details concerning prior antibiotic exposure are
unknown, combination empiric therapy directed against
Gram-negative bacteria would be reasonable to increase
the likelihood of appropriate therapy, until susceptibility
data become available. Given the importance of prior
antibiotic exposure as a risk factor for antibiotic resis-
tance, inappropriate therapy, and increased mortality,
and the availability of electronic medical records at
many hospitals, institutions should try to formalize an
approach for identifying prior antibiotic exposure in
patients with serious infections.
Abbreviations
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Figure 2 Bar graph depicting total hospital costs and
individual cost centers costs. Black bars represent patients with
prior antibiotic exposure and white bars represent patients without
prior antibiotic exposure. ICU = intensive care unit, Pharm =
pharmacy, Lab = laboratory, RT = respiratory therapy, OR =
operating room, RAD = radiology, Misc = miscellaneous.
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